1. Scrip
  2. >>Focus On Asia
  3. >>China

Chi-Med Extends Oncology Commercial Reach To Realize China Potential

Sales Force Grows Nearly 10-Fold

 
• By Brian Yang

Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.

China flag with arrow graph going up showing strong economy and shares rise. Profit and success. Isolated vector illustration.
CHIMED EXPANDS COMMERCIAL ACTIVITIES IN CHINA TO DRIVE GROWTH FOR CANCER DRUG • Source: Shutterstock

In recent years, China has been at the forefront of oncology development in some areas, given its increasingly aging society and changing lifestyles, coupled with a large population of smokers. The government has been expanding access to newer therapies via insurance coverage and national reimbursement negotiations.

Eager to capture the rapid expansion in market scale as a result of the reimbursement coverage, Hutchison China MediTech...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China’s BRL Gears Up For First UCAR-T Trial In Leukemia/Lymphoma

 
• By Xu Hu

Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.

BeBetter, Trinomab Advance IPOs On China’s STAR Market In Firsts Since Policy Easing

 
• By Dexter Jie Yan

BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.

Chinese Biotechs Raise New Funds On Potential First-In-Class Assets

 
• By Dexter Jie Yan

Helped by their development of novel potential first-in-class therapies, Tcelltech, BioTroy and Xiaolu are among the Chinese ventures to have attracted new funding from investors over the past weeks.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 
• By Dexter Jie Yan

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

More from Focus On Asia